Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2020

24.04.2020 | Original Article – Cancer Research

Afatinib is active in osteosarcoma in osteosarcoma cell lines

verfasst von: Marlid Cruz-Ramos, Yessica Zamudio-Cuevas, Daniel Medina-Luna, Karina Martínez-Flores, Gabriela Martínez-Nava, Javier Fernández-Torres, Alberto López-Reyes, Flavio Solca

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Osteosarcoma is the most common bone tumor, mainly affecting adolescents and young adults, and metastatic disease has poor outcomes with a dismal overall survival. Currently, chemotherapy is the standard of care with limited results, finding that new therapies could improve these outcomes. Preclinical and clinical studies have suggested a possible important role of ErbB pathway aberrations in osteosarcoma etiology. The present study shows the effect of afatinib, an irreversible ErbB family blocker in osteosarcoma cell lines.

Methods

Within a panel of human osteosarcoma cell lines, we addressed cell viability assay using afatinib at increasing concentrations. Motility was measured in wound-healing assays and invasion capacity was assessed in Transwell chamber assays. Finally, to monitor ErbB pathway modulation by afatinib and related compounds, we used Western blot analyses.

Results

Cell viability inhibition, as well as a reduction of motility and migration of osteosarcoma cell line were observed after treatment with afatinib. Likewise, in the HOS cell line, afatinib decreased phosphorylation of key components in the ErbB signaling pathway.

Conclusions

Afatinib shows relevant antitumor effect in several osteosarcoma cell lines, as it causes a significant impact on cell viability, motility, and migration with a significant decrease in the activation of ErbB pathway activity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Bacci G, Briccoli A, Rocca M et al (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14(7):1126–1134. https://doi.org/10.1093/annonc/mdg286CrossRefPubMed Bacci G, Briccoli A, Rocca M et al (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14(7):1126–1134. https://​doi.​org/​10.​1093/​annonc/​mdg286CrossRefPubMed
Zurück zum Zitat Gvozdenovic A, Boro A, Born W et al (2017) A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model. Am J Cancer Res 7(7):1435–1449PubMedPubMedCentral Gvozdenovic A, Boro A, Born W et al (2017) A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model. Am J Cancer Res 7(7):1435–1449PubMedPubMedCentral
Zurück zum Zitat Machiels JPH, Haddad RI, Fayette J et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594. https://doi.org/10.1016/S1470-2045(15)70124-5CrossRefPubMed Machiels JPH, Haddad RI, Fayette J et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594. https://​doi.​org/​10.​1016/​S1470-2045(15)70124-5CrossRefPubMed
Metadaten
Titel
Afatinib is active in osteosarcoma in osteosarcoma cell lines
verfasst von
Marlid Cruz-Ramos
Yessica Zamudio-Cuevas
Daniel Medina-Luna
Karina Martínez-Flores
Gabriela Martínez-Nava
Javier Fernández-Torres
Alberto López-Reyes
Flavio Solca
Publikationsdatum
24.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-020-03220-y

Weitere Artikel der Ausgabe 7/2020

Journal of Cancer Research and Clinical Oncology 7/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.